Alpha 2.0
Login Register
» Authors » David H Henry

David H Henry

Explore the profile of David H Henry including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 62
Citations 2047
Followers 0
Related Specialties
Oncology
Hematology
Pharmacology
Top 10 Co-Authors
Lee Ratner
Ariela Noy
Ronald Mitsuyasu
Jeannette Y Lee
Juan Carlos Ramos
Ethel Cesarman
Amy Chadburn
Joseph A Sparano
Richard F Ambinder
David Aboulafia
Published In
J Clin Oncol
Am J Hematol
Eur J Cancer
Support Care Cancer
Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial
Mittelman M, Henry D, Glaspy J, Tombak A, Harrup R, Kim I, et al.
Am J Hematol . 2024 Jun; 99(9):1778-1789. PMID: 38884137
In patients with lower-risk myelodysplastic syndromes/neoplasms (MDS), response to first-line therapy is limited and transient. The MATTERHORN randomized, double-blind, phase 3 trial evaluated roxadustat versus placebo for patients with transfusion-dependent,...
2.
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
Rubinstein P, Moore P, Bimali M, Lee J, Rudek M, Chadburn A, et al.
Lancet Haematol . 2023 Aug; 10(8):e624-e632. PMID: 37532416
Background: Brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (AVD) is approved in the upfront setting for advanced stage classical Hodgkin lymphoma (cHL). People living with HIV have been...
3.
Open-label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies
Glaspy J, Gabrail N, Locantore-Ford P, Lee T, Modelska K, Samal V, et al.
Am J Hematol . 2023 Jan; 98(5):703-711. PMID: 36710399
Anemia is a common side effect of myelosuppressive chemotherapy; however, chemotherapy-induced anemia (CIA) management options are suboptimal. We evaluated the efficacy and safety of roxadustat in this setting. This open-label...
4.
A retrospective analysis of venous thromboembolism trends in chemotherapy-induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration
Bryer E, Kallan M, Chiu T, Scheuba K, Henry D
EJHaem . 2022 Jul; 1(1):35-43. PMID: 35847693
Background: Patients receiving a variety of chemotherapy regimens often develop chemotherapy-induced anemia (CIA), which contributes to poor outcomes including increased mortality. Prompt and effective treatment of CIA is essential to...
5.
Lenalidomide and the Expanding Toolkit to Manage Kaposi Sarcoma
Henry D, Maki R
Clin Cancer Res . 2022 Apr; 28(12):2485-2487. PMID: 35380669
Lenalidomide recently was shown to have clinical activity in patients with human immunodeficiency virus-associated Kaposi sarcoma. Immunomodulatory imine drugs thus provide another tool in the treatment of this challenging neoplasm....
6.
Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach
Jacobson D, Cadieux B, Higano C, Henry D, Bachmann B, Rehn M, et al.
J Bone Oncol . 2022 Apr; 34:100423. PMID: 35378840
Background: Clinical practice guidelines recommend the use of bone-targeting agents for preventing skeletal-related events (SREs) among patients with bone metastases from solid tumors. The anti-RANKL monoclonal antibody denosumab is approved...
7.
Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study
Henry D, Glaspy J, Harrup R, Mittelman M, Zhou A, Carraway H, et al.
Am J Hematol . 2021 Nov; 97(2):174-184. PMID: 34724251
Anemia is the predominant cytopenia in myelodysplastic syndromes (MDS) and treatment options are limited. Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia of chronic...
8.
Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD)
Makharadze T, Boccia R, Krupa A, Blackman N, Henry D, Gilreath J
Am J Hematol . 2021 Oct; 96(12):1639-1646. PMID: 34653287
Erythropoiesis-stimulating agents (ESA) are effective for chemotherapy-induced anemia (CIA) but associated with serious adverse events. Safer alternatives would be beneficial in this population. The efficacy and safety of ferric carboxymaltose...
9.
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma
Sparano J, Lee J, Kaplan L, Ramos J, Ambinder R, Wachsman W, et al.
Haematologica . 2020 Feb; 106(3):730-735. PMID: 32107337
Four cycles of rituximab plus CHOP chemotherapy is as effective as 6 cycles in low-risk diffuse large B-cell lymphoma (DLBCL). Here we report a post-hoc analysis of a prospective clinical...
10.
A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC
Gascon P, Nagarkar R, Smakal M, Syrigos K, Barrios C, Sanchez J, et al.
J Thorac Oncol . 2019 Oct; 15(2):190-202. PMID: 31629060
Introduction: This study evaluated noninferiority of darbepoetin alfa versus placebo for overall survival (OS) and progression-free survival (PFS) in anemic patients with NSCLC treated to a 12.0-g/dL hemoglobin (Hb) ceiling....